Composition for differential diagnosis of urothelial papilloma

WO2025033900A1PCT designated stage expired Publication Date: 2025-02-13IND ACADEMIC COOP FOUND YONSEI UNIV +4
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/011505
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-09
Filing Date
2024-08-05
Publication Date
2025-02-13

Smart Images

  • Figure KR2024011505_13022025_PF_FP_ABST
    Figure KR2024011505_13022025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a composition for differential diagnosis of urothelial papilloma, and an information provision method using same. By using the composition and the information provision method of the present invention, urothelial papilloma can be distinguished from low-grade urothelial carcinoma, which had been difficult to distinguish by tumor morphological shape in a conventional histopathological examination.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for differential diagnosis of urothelial papilloma

[0001] The present invention relates to a composition for differential diagnosis of urothelial papilloma and its use.

[0002]

[0003] Approximately 95% of tumors that arise from the bladder are epithelial tumors, and most of these are composed of the urothelium, so they are called urothelial tumors or transitional epithelial tumors. These urothelial tumors can be classified histologically, and according to the WHO (2003) / ISUP system, they can be classified into urothelial papilloma (UP), low-grade papillary urothelial carcinoma (LG-PUC), and high-grade papillary urothelial carcinoma (HG-PUC).

[0004] Urothelial papilloma is difficult to distinguish histomorphologically from low-grade papillary urothelial carcinoma, and there is currently no pathological diagnostic marker that can differentiate between the two diseases.

[0005]

[0006] The purpose of the present invention is to provide a composition for differential diagnosis of urothelial papilloma.

[0007] The purpose of the present invention is to provide a method for providing information for differential diagnosis of urothelial papilloma.

[0008]

[0009] 1. A composition for differential diagnosis of urothelial papilloma, comprising a preparation capable of measuring the expression level of KRT18 protein or a gene encoding the same.

[0010] 2. A composition for differential diagnosis of urothelial papilloma, which can diagnose urothelial papilloma by differentiating it from low-grade papillary urothelial carcinoma in the above 1.

[0011] 3. In the above 1, a composition for differential diagnosis of urothelial papilloma, wherein the agent capable of measuring the expression level of the protein is a monoclonal antibody, polyclonal antibody, chimeric antibody, ligand, PNA (peptide nucleic acid), aptamer or nanoparticle that specifically binds to the protein.

[0012] 4. A composition for differential diagnosis of urothelial papilloma, wherein the agent capable of measuring the expression level of the gene encoding the protein in the above 1 is a primer pair, probe or antisense nucleotide that specifically binds to the gene.

[0013] 5. A kit for differential diagnosis of urothelial papilloma, comprising the composition described in any one of items 1 to 4 above.

[0014] 6. A method for providing information for diagnosing urothelial papilloma, comprising a step of measuring the expression level of KRT18 protein or a gene encoding the same in a biological sample obtained from an individual.

[0015] 7. In the above 6, the biological sample is a tumor tissue, a method for providing information for diagnosing urothelial papilloma.

[0016] 8. A method for providing information for diagnosing urothelial papilloma, further comprising a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it in the above 6 is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma.

[0017] 9. A method for providing information on the prognosis of urothelial papilloma, which provides information that the lower the content of KRT18 in a biological sample obtained from an individual, the higher the probability of progression to cancer compared to an individual without such content.

[0018] 10. In the above 9, the biological sample is a tumor tissue, a method for providing information on the prognosis of urothelial papilloma.

[0019] 11. A method for diagnosing urothelial papilloma, comprising the step of measuring the expression level of KRT18 protein or a gene encoding the same in a biological sample obtained from an individual.

[0020] 12. A method for diagnosing urothelial papilloma, wherein the biological sample is a tumor tissue in the above 11.

[0021] 13. A method for diagnosing urothelial papilloma, further comprising a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it in the above 11 is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma.

[0022]

[0023] Using the composition and information providing method of the present invention, it is possible to differentially diagnose urothelial papilloma from low-grade papillary urothelial carcinoma. In particular, using the composition and information providing method of the present invention, it is possible to distinguish between urothelial papilloma and low-grade papillary urothelial carcinoma, which were difficult to distinguish based on the morphological appearance of the tumors in conventional histopathological examinations.

[0024]

[0025] Figure 1 shows KRT18 and EHD4, which are high-ranking proteins in differentiating UP and PUC based on machine learning.

[0026] Figure 2 shows the results of immunohistochemical staining for EHD4. No significant difference was observed between UP and LG-PUC (p=0.7).

[0027] Figure 3 confirmed that the expression of KRT18 was upregulated in UP, but the level was not significant (p=0.3).

[0028] Figure 4 confirms that the expression of KRT18 was significantly overexpressed in the UP of the expanded internal validation cohort (p=0.0028).

[0029] Figure 5 confirms that the expression of KRT18 was significantly upregulated in UP even in an external validation cohort (p<0.0001).

[0030] The horizontal bars in Figures 2 to 5 represent the median. (Mann-Whitney test, p: ns, not significant; **<0.01; ****<0.0001)

[0031] Figure 6 is an evaluation of the KRT18 level threshold, which is set to KRT18 level ≤ 4 to distinguish between UP and LG-PUC.

[0032] Figure 7 is an ROC curve in the internal validation cohort (area under curve [AUC]=0.7284, p=0.004).

[0033] Figure 8 is an ROC curve in an external validation cohort (area under curve [AUC]=0.8259, p<0.0001).

[0034] Figure 9 shows the microscopic findings in four "advanced urothelial papillomas (advanced UPs)". After 58 months (A) and 14 months (B), the cases progressed to low-grade papillary urothelial carcinoma (LG-PUC), after 187 months (C) to muscle-invasive bladder cancer, and after 84 months to urothelial carcinoma in situ. The scale bar represents 400 μm.

[0035] Figure 10 shows the results of proteomic analysis, which confirmed KRT18 abundance in one “progressive UP” (Figure 9A) and eight “non-progressive UPs.”

[0036] Figure 11 shows the results of internal and external validation tests, showing that immunostaining for KRT18 in UP was significantly reduced in “progressive UP” (***p=0.0008).

[0037] Figure 12 summarizes the experimental process, where FASP stands for filter aided sample preparation, FFPE stands for formalin-fixed paraffin-embedded, IHC stands for immunohistochemistry, LC-MS / MS stands for liquid chromatography with tandem mass spectrometry, LG-PUC stands for low-grade papillary urothelial carcinoma, and UP stands for urothelial papilloma.

[0038]

[0039] Hereinafter, the present invention will be described in detail.

[0040] The present invention provides a composition and a method for diagnosing urothelial papilloma.

[0041] Specifically, the present invention provides a diagnostic composition and diagnostic method for urothelial papilloma, which can accurately and quickly distinguish between urothelial papilloma and low-grade urothelial carcinoma, which were difficult to distinguish based on the morphological appearance of the tumor in conventional histopathological examinations, by using the KRT18 protein as a marker for diagnosis.

[0042] The present invention provides a composition for differential diagnosis of urothelial papilloma, comprising a preparation capable of measuring the expression level of KRT18 protein or a gene encoding the same.

[0043] The above composition can diagnose and differentiate urothelial papillary urothelial carcinoma from low-grade papillary urothelial carcinoma.

[0044] The term "KRT18 (Keratin 18)", also known as CK-18, CYK18, K18, and keratin 18, encodes the body's type Ⅰ intermediate filament chain keratin 18.

[0045] The term "urothelial papilloma (UP)" refers to a benign, epithelial tumor composed of a fibrovascular core covered by normal-appearing urothelium. UP is histologically difficult to differentiate from low-grade papillary urothelial carcinoma.

[0046] The term "low-grade papillary urothelial carcinoma (LG-PUC)" is based on the histological grading system of WHO / ISUP and, unlike urothelial papilloma, is a malignant tumor.

[0047] The term "diagnosis" means confirming the presence or characteristics of a pathological condition.

[0048] The term "differential diagnosis" means identifying the presence or characteristics of a pathological condition in order to distinguish it from other diseases.

[0049] In one example, we confirmed that UP had high KRT18 IHC (immunohistochemistry) levels, while LG-PUC had low KRT18 IHC levels. In the internal cohort, when distinguishing UP (test) from LG-PUC (control) based on KRT18 IHC levels ≤4, the sensitivity was 66.67% (95% confidence interval 47.82% to 81.36%) and the specificity was 74.07% (95% confidence interval 55.32% to 86.83%) (Fig. 7, Table 1). In the external cohort, when differentiating UP and LG-PUC based on KRT18 IHC level 4 or lower, the sensitivity was 77.78% (95% confidence interval 61.92% to 88.28%) and the specificity was 66.67% (95% confidence interval 48.78% to 80.77%) (Fig. 8, Table 2).

[0050] The measurement of the expression level of the above KRT18 protein is a process of confirming the presence of the KRT18 protein and the expression level of the protein in a biological sample obtained from an individual for the differential diagnosis of urothelial papilloma, and confirming the amount of the protein using a molecule that specifically binds to the protein.

[0051] The agent capable of measuring the expression level of the above protein may be, but is not limited to, a monoclonal antibody, polyclonal antibody, chimeric antibody, ligand, peptide nucleic acid (PNA), aptamer, or nanoparticle that specifically binds to the above protein.

[0052] Analytical methods for this purpose include, but are not limited to, Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunoprecipitation assay, immunohistochemical analysis, complement fixation assay, fluorescence activated cell sorter (FACS), or protein chip.

[0053] Measurement of the expression level of the gene encoding the above protein is a process of confirming the presence and expression level of the gene encoding KRT18 in a biological sample obtained from an individual for the differential diagnosis of urothelial papilloma, and confirming the amount of the gene using a molecule that specifically binds to the gene.

[0054] The agent capable of measuring the expression level of the gene encoding the above protein may be, but is not limited to, a primer pair, a probe, or an antisense nucleotide that specifically binds to the above gene.

[0055] Analytical methods for this include, but are not limited to, reverse transcriptase-polymerase chain reaction (RT-PCR), real-time polymerase chain reaction, RNase protection assay (RPA), Northern blotting, and DNA chips.

[0056] The present invention provides a kit for differential diagnosis of urothelial papilloma comprising the above composition.

[0057] The above kit can perform a differential diagnosis of urothelial papilloma using a biological sample isolated from an individual. Specifically, the kit can perform a differential diagnosis of urothelial papilloma using a tumor sample collected from an individual.

[0058] The above kit may include not only a preparation for measuring the expression level of the protein or gene, but also tools, reagents, etc. commonly used in immunological analysis.

[0059] Examples of the above tools or reagents may include, but are not limited to, a suitable carrier, a label capable of generating a detectable signal, a chromophore, a solubilizer, a detergent, a buffer, a stabilizer, and the like. When the label is an enzyme, the substrate capable of measuring the enzyme activity and a reaction terminator may be included. The carrier may be a soluble carrier or an insoluble carrier. An example of a soluble carrier is a physiologically acceptable buffer known in the art, such as PBS, and an example of an insoluble carrier may be a polymer such as a magnetic microparticle plated with a metal such as polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, fluororesin, cross-linked dextran, polysaccharide, latex, etc., other paper, glass, metal, agarose, and combinations thereof.

[0060] The composition and differential diagnosis are as described above.

[0061] The present invention provides a method for providing information for diagnosing urothelial papilloma, comprising a step of measuring the expression level of KRT18 protein or a gene encoding the same in a biological sample obtained from an individual.

[0062] The expression level of the above KRT18 protein can be measured using protein chip analysis, immunoassay, Ligand binding assay, MALDI-TOF (Matrix desorption / Ionization time of flight mass spectrometry) analysis, SELDI-TOF (Sulface enhanced laser desorption / Ionization time of flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunodiffusion, Oukteroni immunodiffusion, rocket immunoelectrophoresis, immunohistochemistry analysis, immunocytochemistry analysis, complement fixation assay, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry), Western blot, and ELISA (enzyme linked immunosorbent assay). In one embodiment, the expression level of KRT18 can be measured via LC-MS / MS.

[0063] The method may further include a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma.

[0064] The term "biological sample" means any sample obtained from an individual from which the expression level of the KRT18 protein or the gene encoding it can be measured.

[0065] The biological sample may be, but is not limited to, blood, plasma, serum, urine, saliva, sputum, cerebrospinal fluid, cell culture, tissue extract, or tumor tissue. Specifically, the sample may be tumor tissue. The biological sample may be prepared by processing using a method commonly used in the art. The present invention provides a method for diagnosing urothelial papilloma, comprising the step of measuring the expression level of the KRT18 protein or a gene encoding the same in a biological sample obtained from an individual.

[0066] The diagnostic method of the present invention may further include a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma.

[0067] The present invention provides a use of a preparation capable of measuring the expression level of the KRT18 protein or a gene encoding it for diagnosing urothelial papilloma.

[0068] The present invention provides a use of a preparation capable of measuring the expression level of KRT18 protein or a gene encoding the same for differential diagnosis of urothelial papilloma.

[0069] The present invention provides a use of a formulation capable of measuring the expression level of a KRT18 protein or a gene encoding the same for the manufacture of a composition for diagnosing urothelial papilloma.

[0070] The above diagnosis, differential diagnosis, biological sample, KRT18, and urothelial papilloma are as described above.

[0071] The present invention provides a method for providing information on the prognosis of urothelial papilloma, which provides information that a lower content of KRT18 in a biological sample obtained from an individual increases the probability of progression to cancer compared to an individual without such content.

[0072] The biological samples, KRT18 and urothelial papilloma, are as described above.

[0073] The present inventors have confirmed that not only is the expression of the KRT18 protein or the gene encoding it higher in UP than in LG-PUC, but also that when the expression of the KRT18 protein or the gene encoding it is lower in UP, there is a possibility of progression to cancer.

[0074]

[0075] Hereinafter, the present invention will be described in detail by way of examples to specifically explain the present invention.

[0076]

[0077] 1. Experimental method

[0078] 1-1. Research sample

[0079] This study included 108 cystectomy specimens obtained from two institutions. For proteomic analysis, 31 specimens were classified as UP (n = 9), PUC (n = 12), and normal urothelial tissue (n = 10). One UP patient developed LG-PUC after 58 months, but the other UP patients did not progress to cancer during follow-up (median, 48 months; range, 8–85 months). At the same institution, 54 low-grade papillary urothelial neoplasms (27 UPs and 27 LG-PUCs; internal cohort) were used to validate selected diagnostic markers by immunohistochemical staining. In addition, 66 low-grade papillary urothelial neoplasms (30 UPs and 36 LG-PUCs; external cohort), independently procured from Yonsei University College of Medicine, Severance Hospital (Seoul, South Korea), were used for external validation. Tumor diagnoses from both centers were reviewed by two experienced urologists (MJ and HSR) according to the latest global health organization classification.

[0080]

[0081] 1-2. Discovery of diagnostic biomarkers for papillary urothelial neoplasms through machine learning feature selection and immunohistochemical validation.

[0082] Support vector machine analysis using a radial basis kernel was performed using Perseus to select proteins that could discriminate between UP and papillary urothelial carcinoma (PUC). The diagnostic value of the shortlisted proteins was validated in an independent cohort of UP and LG-PUC using immunohistochemical staining on a BenchMark ULTRA automated stainer (Roche, Rotkreuz, Switzerland). Primary antibodies against EHD4 (cat. # PA5-30717, Thermo Fisher, Waltham, MA, US) and KRT18 (cat. # CSB-MA000253, Cusabio, Houston, TX, US) were used. Protein expression was evaluated as the sum of the scores for staining degree (negative = 0, 1%-33% = 1, 34%-66% = 2, 67%-100% = 3) and intensity (negative = 0, weak = 1, moderate = 2, strong = 3). To compare immunoexpression, the Mann-Whitney test was performed using GraphPad Prism ver. 9.4.1 (GraphPad Software, San Diego, California US).

[0083]

[0084] 1-3. Identification of urothelial carcinoma after urothelial papilloma (UP)

[0085] We reviewed patients with UP diagnosed between 2000 and 2022, including all patients analyzed by proteomics and immunohistochemistry, for the development of urothelial carcinoma after UP. Patients with a history of urothelial carcinoma on biopsy, concurrent urothelial carcinoma, or those lost to follow-up were excluded. Follow-up included urine cytology, urine analysis, cystoscopy, computed tomography, or magnetic resonance imaging. The frequency and method of follow-up were determined at the clinician's discretion. UP that progressed to urothelial carcinoma after the initial diagnosis was designated as "advanced UP," whereas UP that did not progress to urothelial carcinoma was designated as "non-advanced UP."

[0086]

[0087] 1-4. Statistical and bioinformatics analysis

[0088] To compare the proteomes between UP, PUC, and normal urothelium groups, one-way analysis of variance (ANOVA) or two-tailed t-tests were performed using Perseus version 1.6.14.0 at a significance level of FDR <0.05. Gene Ontology-Biological Process (GOBP) functional enrichment analysis was performed using ToppGene Suite. Protein-protein interactions (PPIs) were retrieved from the String database and networks were built using Cytoscape. Statistical significance was determined at a p-value of <0.05.

[0089]

[0090] 2. Results

[0091] 2-1. We identified KRT18, a new diagnostic marker for urothelial papilloma, through proteomic-based machine learning analysis and external validation.

[0092] To identify novel biomarkers that facilitate the differential diagnosis of low-grade papillary neoplasms, we performed machine learning analysis using support vector machines. KRT18 and EHD4, with the lowest error rate of 8.27%, were selected as the most suitable candidates for distinguishing UP from PUC (Figure 1).

[0093] To confirm its usefulness in real-world diagnostics, we conducted validation in two independent cohorts of UP and LG-PUC patients. First, immunohistochemical staining for EHD4 and KRT18 was performed in a small internal cohort consisting of three UP patients and three LG-PUC patients. EHD4 expression did not differ between individuals (p=0.7) (Fig. 2). Similarly, KRT18 appeared to be upregulated in UP patients, but not significantly (p=0.3) (Fig. 3).

[0094] Therefore, we conducted an external validation using a total of 54 internal specimens (13 UP, 10 LG-PUC) from Seoul National University Hospital, and confirmed that KRT18 expression was significantly upregulated in UP (p=0.0028) (Fig. 4). In addition, an external validation using 66 papillary tumors (30 UP, 36 LG-PUC) from Severance Hospital also consistently showed that KRT18 was expressed at a higher level in UP than in LG-PUC (p<0.0001) (Fig. 5).

[0095] Furthermore, based on the above verification results, the immunohistochemical threshold of KRT 18 for distinguishing LG-PUC from UP was confirmed through the ROC curve and Youden's index (Figs. 6 to 8, Tables 1 and 2). The ROC curves of the internal and external cohorts are shown in Figs. 7 and 8, respectively, and the specific values ​​of sensitivity, specificity, 95% confidence intervals, and Youden's index in the internal and external cohorts are shown in Tables 1 and 2, respectively.

[0096]

[0097] KRT18 threshold Sensitivity%95% CISpecificity%95% CIYouden's index03.7040.19% to 18.28%92.5976.63% to 98.68%-3.706≤225.9313.17% to 44.68%88.8971.94% to 96.15%14.82≤348.1530.74% to 66.01%88.8971.94% to 96.15%37.04≤466.6747.82% to 81.36%74.0755.32% to 86.83%40.74≤585.1967.52% to 94.08%44.4427.59% to 62.69%29.63

[0098] KRT18 thresholdSensitivity%95% CISpecificity%95% CIYouden's index02.7780.1425% to 14.17%10088.65% to 100.0%2.778≤222.2211.72% to 38.08%10088.65% to 100.0%22.22≤338.8924.78% to 55.14%96.6783.33% to 99.83%35.56≤477.7861.92% to 88.28%66.6748.78% to 80.77%44.45≤510090.36% to 100.0%43.3327.38% to 60.80%43.33

[0099]

[0100] Based on the ROC curve and the highest Youden's index, a KRT18 IHC level of ≤4 was selected as the optimal threshold for differentiating UP and LG-PUC in both the internal and external cohorts. The classification accuracy was 0.70 in the internal cohort and 0.73 in the external cohort.

[0101]

[0102] 2-2. KRT18 downregulation can predict malignant progression of urothelial papilloma (UP).

[0103] Because quantitative protein analysis identified KRT18 as a marker for urothelial tumors, we further investigated whether KRT18 expression could predict the development of urothelial carcinoma after UP. First, we investigated the risk of progression to urothelial carcinoma in patients previously diagnosed with UP. We excluded patients with a prior history, concurrent diagnosis of urothelial carcinoma, or those lost to follow-up, and evaluated 74 and 68 patients from two participating institutions, respectively. The median follow-up periods were 43 months (range, 1-187) and 40.5 months (range, 1-164), respectively. After diagnosis of UP, 4 (5.4%) and 1 (1.5%) patients developed urothelial carcinoma after UP, consisting of 3 LG-PUC, 1 urothelial carcinoma in situ, and 1 muscle-invasive urothelial carcinoma, respectively, at 14, 16, 58, 84, and 187 months after diagnosis of UP. Histologically, “advanced UP” showed mature urothelial cells with well-formed fibrovascular cores and minimal cytological atypia (Fig. 9), and was morphologically indistinguishable from classical UP.

Claims

1. A composition for differential diagnosis of urothelial papilloma, comprising a preparation capable of measuring the expression level of KRT18 protein or a gene encoding the same.

2. A composition for differential diagnosis of urothelial papilloma, which can diagnose and differentiate urothelial papilloma from low-grade papillary urothelial carcinoma according to claim 1.

3. A composition for differential diagnosis of urothelial papilloma, wherein the agent capable of measuring the expression level of the protein according to claim 1 is a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a ligand, a PNA (peptide nucleic acid), an aptamer or a nanoparticle that specifically binds to the protein.

4. A composition for differential diagnosis of urothelial papilloma, wherein the agent capable of measuring the expression level of the gene encoding the protein according to claim 1 is a primer pair, probe or antisense nucleotide that specifically binds to the gene.

5. A kit for differential diagnosis of urothelial papilloma, comprising a composition according to any one of claims 1 to 4.

6. A method for providing information for diagnosing urothelial papilloma, comprising the step of measuring the expression level of KRT18 protein or a gene encoding it in a biological sample obtained from an individual.

7. A method for providing information for diagnosing urothelial papilloma, wherein the biological sample according to claim 6 is a tumor tissue.

8. A method for providing information for diagnosing urothelial papilloma, further comprising a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma in claim 6.

9. A method for providing information on the prognosis of urothelial papilloma, which provides information that a lower content of KRT18 in a biological sample obtained from an individual has a higher probability of progressing to cancer compared to an individual without the lower content of KRT18.

10. A method for providing information on the prognosis of urothelial papilloma, wherein the biological sample is a tumor tissue according to claim 9.

11. A method for diagnosing urothelial papilloma, comprising the step of measuring the expression level of KRT18 protein or a gene encoding it in a biological sample obtained from an individual.

12. A method for diagnosing urothelial papilloma according to claim 11, wherein the biological sample is a tumor tissue.

13. A method for diagnosing urothelial papilloma according to claim 11, further comprising a step of diagnosing urothelial papilloma when the expression level of the KRT18 protein or the gene encoding it is increased compared to the expression level measured in a biological sample obtained from a patient with low-grade papillary urothelial carcinoma.

Citation Information

Patent Citations

  • Chromogranin A as a marker for bladder cancer

    JP6831852B2

  • Diagnosis of urothelial cancer

    WO2015150834A1

  • Method for predicting the response to cancer immunotherapy in cancer patients

    WO2020109570A1